Nvidia-ARM deal runs into security issues in the UK
By Peter Clarke, eeNews Europe (April 22, 2021)
The UK government has issued a public interest intervention notice instructing investigators to look into Nvidia's proposed $40 billion acquisition of ARM from SoftBank.
Nvidia's share price dropped a few percent on the news of the intervention, which has been invoked to give the UK Competition and Markets Authority (CMA) time to report on multiple issues including jurisdictional, competition and national security issues.
The CMA had already announced an investigation of the deal back in January 2021, but that was only based on competition considerations alone. The government's invocation includes that but adds the aspect of national security considerations.
The next process starts with a repeated first look at the circumstances and implications of a merger and will include third-party views – which in the case of Nvidia-ARM have been consistently opposed to the deal. The CMA has until July 30, 2020, to return its phase one report at which point the politicians have a choice to either allow the transaction or invoke a more rigorous phase two investigation.
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
Related News
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- SiFive and Kinara Partner to Offer Bare Metal Access to RISC-V Vector Processors
- Imagination Announces E-Series: A New Era of On-Device AI and Graphics
- Siemens to accelerate customer time to market with advanced silicon IP through new Alphawave Semi partnership
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design